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Selectivitya b s t r a c t
Protein–protein interactions (PPIs) are important targets for the development of chemical probes and
therapeutic agents. From the initial discovery of the existence of hot spots at PPI interfaces, it has been
proposed that hot spots might provide the key for developing small-molecule PPI inhibitors. However,
there has been no review on the ways in which the knowledge of hot spots can be used to achieve inhib-
itor design, nor critical examination of successful examples. This Digest discusses the characteristics of
hot spots and the identiﬁcation of druggable hot spot pockets. An analysis of four examples of hot
spot-based design reveals the importance of this strategy in discovering potent and selective PPI inhib-
itors. A general procedure for hot spot-based design of PPI inhibitors is outlined.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).Protein–protein interactions (PPIs) play a pivotal role in most
biological processes. The interface between two proteins typically
has an area of 1500–3000 Å2 with approximately 750–1500 Å2 of
surface area buried in each protein.1–3 The formation of a pro-
tein–protein complex is largely driven by hydrophobic effects,4
which occur between the nonpolar regions of protein residues
through van der Waals contacts. Electrostatic complementarity of
the interacting protein surfaces between two proteins promotes
the formation and lifetime of the complex. For some interfaces
hydrogen bonding and electrostatic interaction play a major role
in steering one protein to dock onto the binding site of the second
protein.
Characteristics of hot spots and hot regions: The residues on the
protein–protein interface do not contribute equally to PPIs. A small
subset of residues contribute to the majority of the binding free
energy; they are called hot spots.5 A hot spot is deﬁned as a residue
which substitution by an alanine leads to a signiﬁcant decrease in
the free energy of binding (DDGbinding > 1.5 kcal/mol).5 The
experiment that involves individually mutating interface residues
to alanine, eliminating side-chain atoms beyond Cb, and then
measuring the effect of individual side chain on binding afﬁnity
is called alanine scanning. A survey of alanine scanning data indi-
cated that the amino acid composition of hot spots was enriched in
tryptophan (W), arginine (R), and tyrosine (Y).6 This trend of resi-
due enrichment was also reproduced by a different surface analysisapproach using clustered interface families.7 Energetic hot spots
from alanine scanning correlate with structurally conserved
residues.8 The number of the structurally conserved residues, in
particular the energetic hot spots, increases with the expansion
of the interacting surface area. Typically, hot spot density on the
protein–protein interface composes 10% of the binding site
residues.9
The free energy of binding between two proteins is not a simple
summation of the contribution from individual hot spots. Hot spots
tend to occur in clusters. Within the cluster, the tightly packed hot
spots are in contact with each other and form a network of con-
served interactions called hot regions.10 One example of hot
regions in a protein–protein interface is shown in Figure 1. The
contributions of hot spots within one hot region are cooperative
to stabilize PPIs. Hot regions are networked and contribute domi-
nantly to the stability of PPIs. The energetic contributions between
two hot regions can be additive11 or cooperative.12
The protruding hot region of one protein packs against the con-
cave hot region of the other protein.4,13 Figure 2 illustrates a typical
arrangement of hot spot and hot region. Residues 1–4 in Figure 2
constitute the top hot region for the interactions between proteins
A and B while residues 5–8 form the bottom hot region. For the top
hot region residues 1 and 3 make a protruding hot region, and res-
idues 2 and 4 create a concave hot region. The projecting hot spot,
residue 1 in Figure 2, makes a direct contact with hot spot 2 in the
concave hot spot pocket. Residue 3 organizes the orientation of
projecting hot spot 1, and 4 supports the structure of the hot spot
pocket. Not only the alanine mutations of hot spots 1 and 2 but also
Figure 1. Crystal structure of b-catenin in complex with T-cell factor (Tcf) shows three hot regions (PDB IDs, 1G3J and 2GL7). Hot region 1 includes K435 and K508 of
b-catenin and D16 and E17 of Tcf4. Hot region 2 includes K312 and K345 of b-catenin and E24 and E29 of Tcf4. Hot region 3 includes F253, I256, F293, A295, and I296 of
b-catenin and V44 and L48 of Tcf4.
Figure 2. Illustration of hot spots and hot regions in the protein–protein interface
(adapted from Golden et al.13). The top hot region has a projecting hot spot, 1, from
protein A. This projecting residue binds to a complementary surface pocket of
protein B, which is lined by residues that are labeled 2. The residues on protein A
that help to orient projecting hot spot 1 are labeled 3. The residues on protein B that
help to form the concave hot region are labeled 4. The bottom hot region has two
projecting hot spots from protein B that are labeled 5. The concave surface pocket
residue of protein A is labeled 6. The residues in protein B that support the
projecting hot spot are labeled 7. The residues in protein A that support the
formation of the concave hot region are labeled 8.
W. Guo et al. / Bioorg. Med. Chem. Lett. 24 (2014) 2546–2554 2547the mutations of residues 3 and 4 would greatly affect the free
energy of binding between proteins A and B. Therefore, residues
1–4 are all called energetic hot spots in the alanine scanning exper-
iments. The projecting hot spots, 1 and 5 in Figure 2, are also
named anchor residues if the change of their solvent accessible
surface areas (SASA) upon binding is >0.5 Å2. 14,15
The concave hot regions are usually pre-organized in the unbound
state prior to protein complexation,14,16 as demonstrated in Figure 3.The existence of such ready-made recognitionmotifs implies that the
binding pathway can avoid kinetically costly structural rearrange-
ment at the core of the binding interface, allowing for a relatively
smooth recognitionprocess.Once theprotrudinghot region isdocked
to the concave hot region, an induced ﬁt process further contributes
to the formation of the ﬁnal high-afﬁnity complex.
Alanine scanning experiments to unravel hot spots are rela-
tively time-consuming and labor-intensive. In some cases, the
results of the alanine scanning experiments could be inconclusive.
For example, the alanine mutation of residues that participate in
forming concave hot regions likely gives rise to nonadditive
DDGbinding values. The alanine mutations could affect the free
energy of binding by a mechanism unrelated to the PPIs at the
interface, for example, by destabilizing the unbound state of the
protein or altering its conformation. Therefore, hot spots identiﬁed
by alanine scanning experiments could be false positives in the
sense that they do not reﬂect energetically important binding
interactions with the partner protein. In addition, alanine scans
could miss a binding hot spot that mostly involves interaction of
backbone rather than side-chain atoms. Computational methods
have been developed to predict hot spots. These methods are com-
plementary to the alanine scanning experiments and provide valu-
able insights into the nature of protein–protein complexation.17
Some computational methods calculate the changes of free energy
of binding upon mutation using calibrated free energy functions,
such as Robetta18 and FOLDEF.19 A second group of computational
methods incorporate molecular dynamics simulations in computa-
tional alanine scanning.20 The third group covers knowledge-based
methods that learn the relationship between hot spots and various
residue features from training data, and then predict new hot
spots.21 Also, hybrid approaches, which integrate the strengths of
the machine learning and energy-based methods, have been devel-
oped and applied to predict protein hot spots.22
Solvation also plays an important role in protein–protein asso-
ciation. Hot spots are often surrounded by energetically less impor-
tant residues that shape like an O-ring to occlude bulk water
molecules from the hot spot.6 The afﬁnity of a hot region depends
not only on the energetically critical hot spots located near the
Figure 3. Pre-organization of the concave hot region in the protein–protein interface. The anti-hen-egg-white lysozyme antibody D1.3/anti-idiotopic antibody E5.2 complex
was used as an example.16 Examination of the two structures reveals that the concave region of D1.3 is formed in both the absence and presence of E5.2. (A) The crystal
structure of the apo antibody D1.3 (PDB id, 1VFB). (B) The crystal structure of the complex of antibodies D1.3 and E5.2 (PDB id, 1DVF).
2548 W. Guo et al. / Bioorg. Med. Chem. Lett. 24 (2014) 2546–2554center of a hot region but also on the surrounding seal of contact-
ing residues that establish the correct solvation environment. The
O-ring structure results in a lower local dielectric constant envi-
ronment and an enhancement of speciﬁc electrostatic and hydro-
gen bond interactions for the polar and ionizable hot spots. The
further development of the O-ring structure led to the ‘double
water exclusion’ hypothesis. This hypothesis not only recognizes
the existence of the hydrophobic O-ring structure but also assumes
some hot spots themselves are water-free.23 Both the O-ring the-
ory24 and the ‘double water exclusion’ hypothesis23,25 explain cer-
tain PPIs.
Druggable hot spot pockets: Protein–protein interfaces have been
recognized as biologically appealing targets for designing small-
molecule chemical probes and/or therapeutic agents. However,
the discovery of such small molecules with desired potency, selec-
tivity, and physicochemical properties has proven challenging.2,3
Protein–protein interfaces tend to be ﬂat, featureless, and rather
large (typically 1500–3000 Å2); while the surface of a protein often
displays complex dynamic behavior. In contrast to enzymes or
receptors that have one or two disproportionately large sub-
strate-binding pockets with an average volume of 260 Å3, pro-
tein–protein interfaces are characterized by several shallow small
pockets with an average volume of 54 Å3 for each pocket.26 These
features make the discovery of potent PPI inhibitors difﬁcult. Nev-
ertheless, the pre-existence of the concave hot spot region on the
unbound protein surface and the complementary packing of two
hot regions from two interacting proteins provide impetus to
search for small-molecule PPI inhibitors. A small-molecule PPI
inhibitor should target 3–5 small pockets in the protein–protein
surface and take advantage of protein adaptability.26 The confor-
mational adaptivity of a protein surface has frequently been
observed when binding with a second protein or a small molecule.3
It is possible that the protein surface adjacent to a concave hot
region undergoes induced-ﬁt to accommodate small-molecule
PPI inhibitors.
Hot spot pockets for PPIs are distinguishable from the other
regions of protein surface due to their concave topology combined
with a pattern of hydrophobic and polar functionality. This combi-
nation of properties confers on concave hot regions a tendency to
bind small organic compounds possessing some polar functionality
decorating a largely hydrophobic scaffold. In other words, concave
hot regions on PPI surfaces are not simply the sites that are com-
plementary to a particular organic functionality but rather possess
a general tendency to bind organic compounds with a variety of
structures. This property of hot regions has been observed in Mul-
tiple Solvent Crystal Structures (MSCS)27 and Structure–Activity
Relationship by Nuclear Magnetic Resonance (SAR by NMR).28MSCS determines the X-ray structures of a target protein in aque-
ous solutions containing high concentrations of organic co-sol-
vents and then superimposes the obtained crystal structures.
Consensus binding sites have been observed from these crystal
structures. A consensus binding site typically accommodates a
number of different organic probes binding in well-deﬁned orien-
tations. SAR by NMR screens a library of fragments using NMR and
identiﬁes the speciﬁc binding pocket for each fragment hit, guiding
the synthesis of larger molecules from the fragments that bind at
multiple binding sites (Fig. 4). A fragment here is deﬁned as a small
organic molecule that follows the ‘‘rule of three’’ 29 (the molecular
weight of the compound 6300, C logP 63, the number of H-bond
donors 63, the number of H-bond acceptors 63, the number of
rotatable bonds 63, and polar surface area (PSA) 660 Å2). The
SAR by NMR studies observed the existence of consensus binding
sites at protein–protein interfaces. Further studies of MSCS and
SAR by NMR demonstrated that these consensus binding sites were
often overlapped with energetic hot regions discovered through
alanine scanning. Starting on a different path, protein phage dis-
play studies demonstrated that short peptides with entirely differ-
ent structural scaffolds bound to the concave hot region and
mimicked the binding mode for native PPIs.30 These observations
provide strong support for the efforts to discover small-molecule
PPI inhibitors.
One should bear in mind that in identifying hot spots, alanine
scanning experiments examine the contributions to the mutual
interaction energy between two proteins, investigating both the
concave and convex PPI regions. In contrast, the ‘consensus binding
site’ derived from MSCS or SAR by NMR is a property of a single
protein, usually the concave PPI surface.31 The energetically
favored region identiﬁed by fragment screening is not necessarily
a PPI hot region as its binding is determined simply by the concav-
ity of the surface pocket and the chemical complementary with
fragment probes. If the structure of the protein–protein complex
and the protruding hot spots are known, the relationship between
the consensus binding sites identiﬁed by fragment screening and
the concave hot regions can be established. FTMap, a computa-
tional solvent mapping program based on the fast Fourier
transform correlation approach, has been used to predict the
consensus binding site for 16 common solvents/small organic mol-
ecules.32 The mapping results of FTMap have a high agreement
with those derived from the X-ray crystallography and NMR stud-
ies.31,33 FTMap is also able to rank the relative importance of the
identiﬁed consensus binding sites.
Inspired by the results of MSCS, SAR by NMR, and computa-
tional solvent mapping, fragment screening has been used to iden-
tify new hits for PPI targets.34 The libraries for fragment screening
Figure 4. Schematic diagram for SAR by NMR. The binding modes of a collection of fragments with target protein are studied by two-dimensional NMR spectra. The fragment
hits from the NMR-based screen are then linked or evolved into drug-like molecules.
W. Guo et al. / Bioorg. Med. Chem. Lett. 24 (2014) 2546–2554 2549contain hundreds to thousands of low-molecular-weight frag-
ments, which are screened at high concentrations. The binding
afﬁnities of commercially available fragments to protein targets
are typically low. Highly sensitive biophysical methods are
required to identify the fragments with weak binding afﬁnities.
The common techniques for fragment screening include NMR,
X-ray crystallography, cysteine engineering-based tethering,35,36
surface plasmon resonance (SPR), thermal shift37 and confocal
ﬂuorescence correlation spectroscopy-based38 assays. These meth-
ods can also be used in a synergistic way.39 Dozens of potent PPI
inhibitors with novel scaffolds have been reported by use of frag-
ment screening coupled with structure-based optimization. Some
well-known examples are the inhibitors for anti-apoptotic protein
BCL-XL/pro-apoptotic protein BAK interactions (Fig. 5A),40 tumor
necrosis factor a (TNF-a)/tumor necrosis factor receptor 1 (TNFR1)
interactions,41 and interleukin-2 (IL-2)/interleukin-2a receptor
(IL-2Ra) interactions.36 It is worth noting that without structural
and biochemical validation the fragments identiﬁed by fragment
screening are not always useful for developing PPI inhibitors. If a
fragment binds to the protein pocket outside the hot region, it
may have no use. Carelessly evolving a fragment hit or linking
two fragment hits might lead to a small molecule that tightly binds
to the target protein but has no effect on disrupting PPIs. The prior
knowledge of hot spots and hot regions derived from biochemical
and crystallographic studies is essential for the success of fragment
screening. An alternative to experimental fragment screening is
hot spot-based virtual screening using a database of fragment-size
molecules. One example is the discovery of 4 in Figure 5B as an
inhibitor for interferon-a (IFN-a)/type I interferon receptor
(IFNAR) interactions.42 NMR and SPR experiments conﬁrm the
direct binding of 4 with IFN-a.
The characteristics of a druggable PPI hot region have been
investigated.48,49 The druggability of a pocket increases logarithmi-
cally with total surface area and apolar contact area, while it
decreases logarithmically with polar contact area. The polar groups
in the druggable binding site play a decisive role in recognizing
drug-like small molecules.50 There is an optimal size and composi-
tion of a protein pocket that is best suited for interacting with
small organic molecules. The druggability of a protein pocket
increases linearly with surface roughness.51 Pocket shape also
has a signiﬁcant inﬂuence on druggability. The optimal value for
pocket compactness (deﬁned as pocket volume divided by pocket
surface area) is 0.4. Large values, corresponding to more spherical
shapes, or small values, corresponding to more elongated shapes,
have a decreased contribution towards druggability. The amino
acid composition around druggable PPI pockets is markedly differ-
ent from that in the other areas on the protein surface. A higher
frequency of aromatic residues and methionine has been observed
in druggable PPI pockets.52 The molecular interplay between
amino acids at a given hot region is also worth attention when
identifying druggable PPI pockets. An increasing number ofcharged residues was reported to have a negative impact on the
druggability of a pocket.48 Furthermore, the conformational ﬂuctu-
ations of the areas adjacent to hot regions due to inherent thermal
motions of a protein could open up transient pockets53 that are
important for accommodating a PPI inhibitor with drug-like
dimensions.54 It was reported that druggable sites on PPIs are more
predisposed than the rest of protein surface and more likely to
accommodate drug-like molecules.55 Indeed, mapping surface
pockets by FTMap with a side-chain conformer generator success-
fully identiﬁed druggable sites in the protein–protein interfaces.56
Case study 1: Due to the facts that: (1) the hot regions of PPIs are
pre-organized on the protein surface and complementarily packed
between two proteins; (2) the hot spots in the concave hot regions
are deeply buried; and (3) the conformational transition to open up
a new pocket for drug-like inhibitors has little energetic cost, it is
arguable that hot spot-based design could be an efﬁcient approach
in discovering drug-like PPI inhibitors. Wang and co-workers have
used hot spot-based design to discover a series of spirooxindole-
containing inhibitors for murine double minute 2 (MDM2)/tumor
suppressor p53 interactions (Fig. 6). The inhibition of MDM2/p53
interactions by small molecules can restore the level of wild-type
p53 and represents an appealing strategy for anticancer therapy.
Crystallographic and biochemical studies revealed that three
hydrophobic residues, F19, W23, and L26 from an a-helix in p53,
form a hot region to interact with a concave hydrophobic hot
region in MDM2. The indole ring of p53 W23 was used as the start-
ing point for inhibitor design, and the spirooxindole structure was
used to build the inhibitor scaffold.57 The oxindole moiety of the
spirooxindole core was designed to mimic the binding mode of
the side chain of p53 W23. Two hydrophobic substituents on the
spirooxindole core, R1 and R2, were designed to mimic the binding
mode of the side chains of F19 and L26, respectively. After the syn-
thesis, compound 5was found to have a Ki value of 0.086 ± 0.02 lM
for disrupting MDM2/p53 PPIs. The optimization resulted in the
discovery of MI-63 with a Ki value of 0.003 ± 0.0015 lM.58 Consis-
tent with its mode of action, MI-63 inhibits the growth of cancer
cells with wild-type p53. Derivation to increase oral bioavailability
and in vivo activity led to MI-21959 and MI-888.60 MI-888 exhibits
a Ki value of 0.00044 ± 0.00022 lM for disrupting MDM2/p53
interactions. This compound induces tumor regression in two
xenograft models in a complete and durable manner.
Case study 2: Dömling, Camacho, and co-workers also performed
hot spot-based design to discover MDM2/p53 PPI inhibitors (Fig. 7).
Residue W23 of p53 was again used as the starting point to initiate
the design. 6-Chloroindole and 4-chlorobenzene were deﬁned as
anchor fragments to mimic the indole ring of p53 W23. Multicom-
ponent reactions (MCRs) were used to produce diverse scaffolds
containing the 6-chloroindolyl or 4-chlorophenyl group.61 The
van Leusen three-component reaction was used to synthesize
WK23, which exhibited a Ki value of 0.916 lM. The crystallographic
analysis of MDM2 in complex with WK23 demonstrated that the
AB
Figure 5. Fragment-based screen to discover PPI inhibitors. (A) The discovery of BCL-XL/BAK inhibitors. Fragments 1 and 2 were identiﬁed by SAR by NMR. They bind at two
proximal subpockets on theBCL-XL surface.Medicinal chemistry optimizationyielded3with aKi value of 0.036 ± 0.002 lMfordisruptingBCL-XL/BAK interactions.43 Subsequent
leadoptimization aimed at removing thebinding tohuman serumalbumin44 and increasing potency to other BCL family proteins,45which led toABT-737.40 Further optimization
was centered to improve oral pharmacokinetics and resulted in the discovery of ABT-263.46 (B) Hot spot-based virtual screening identiﬁed 4 as an inhibitor for IFN-a/IFNAR
interactions. 42 Pharmacophoremodel (green, lipophilic center; blue, hydrogen-bond donor; red, hydrogen-bond acceptor) inside the binding pocket of INF-a and a docking pose
of 4 in IFN-awere provided. LE, ligand efﬁciency; it is deﬁned as free energy of ligand binding (DDG = RTlnKd orDDG = RTlnKi, R: gas constant, T, Kelvin temperature used in
the assays) divided by the number of non-hydrogen atoms of the tested compound.47
2550 W. Guo et al. / Bioorg. Med. Chem. Lett. 24 (2014) 2546–25546-chloroindole moiety ofWK23 was located at the same position as
the side chain of p53 W23. The 6-chlorine atom of WK23 is posi-
tioned towards the very bottom of this concave hot region.62 The
nitrogen atom of 6-chloroindole forms a hydrogen bond with L54
carbonyl oxygen of MDM2 and mimics the binding mode of the
indole nitrogen of p53W23. The 4-chlorobenzyl group and the phe-
nyl rings of WK23 occupy the L26 and F19 binding sites of p53,
respectively. Further modiﬁcation of the WK23 structure led to
the generation of WK298 exhibiting a Ki value of 0.109 lM. The
Ugi four-component reaction was used to generate KK27163,
YH23964, and 665, which had Ki values of 1.2, 0.4, and 0.25 lM,
respectively. A crystallographic analysis revealed a conformational
change of the aromatic residues around the p53 F19/W23/L26 bind-
ing site.66 The 4-chlorobenzyl group was introduced to YH119 to
generate YH300 with a Ki value of 0.6 lM.
Case study 3: Crews, Ciulli, and co-workers designed inhibitors for
von Hippel-Lindau (VHL)/hypoxia-inducible factor 1a (HIF1a) inter-
actions (Fig. 8).67 The VHL protein is a component of the E3 ligase.
The formation of the VHL/HIF1a complex promotes the ubiquitina-
tion and degradation of HIF1a by the proteasome. The accumulation
ofHIF1aupregulates the genes that are involved inhypoxic response,and VHL/HIF1a inhibitors can potentially be used to treat chronic
anemia. 3-Hydroxyl-L-proline (Hyp) 564 of HIF1a is a hot spot for
interacting with VHL. This residue was used as a starting point to
design new inhibitors with the assistance of de novo design software
BOMB.68 Compound 8 was discovered to exhibit an IC50 value of
117 ± 10 lM. The isoxazolemoiety of8was designed to interactwith
a crystallographic water observed in the VHL/HIF1a complex. The
benzyl group of 8 was designed to stack with the side chain of Y98.
Anoxazole ringwas then introduced to theparapositionof thebenzyl
group, resulting in 9 with an IC50 value of 4.1 ± 0.4 lM. Crystallo-
graphic analysis showed that the nitrogen atom of the oxazole ring
formed an H-bond with R107 of VHL, and the C–H at position 2 of
the oxazole ring in 9 formed a nonclassical H-bondwith the carboxyl
oxygenofP99. Further optimization led to thegenerationof10. In this
compound the 4-methylthiazole ring replaced the oxazole ring,
resulting in better interactions with a hydrophobic pocket in VHL.
A substitutedanilinewasused to replace the isoxazolmethylmoiety.
Crystallographic analysis showed that the aniline ring lay adjacent
to the side chain of W88 and made a water-mediated H-bond with
Q96 of VHL. This compound exhibited improved potency, with an
IC50 value of 0.90 ± 0.03 lM.69
Figure 6. Hot spot-based design of spirooxindole-containing MDM2/p53 PPI inhibitors. LE, ligand efﬁciency.
Figure 7. Anchor-oriented design of chloroindole-containing MDM2/p53 PPI inhibitors.
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Figure 8. Hot spot-based design of hydroxyproline-containing VHL/HIF1a PPI inhibitors.
2552 W. Guo et al. / Bioorg. Med. Chem. Lett. 24 (2014) 2546–2554Case study 4: Ji and coworkers used fragment hopping70 to initi-
ate the design of potent and selective PPI inhibitors. Fragment hop-
ping requires the extraction of key binding elements based on the
binding mode between the projecting hot spots and the concave
hot spot pocket. The bioisosteric replacement technique is then
used to design new fragments that match the proposed critical
binding elements and generate new inhibitor structures with the
chemotypes that do not exist in hot spots. As the ﬁrst case study
for PPI targets, this approach was employed to design potent and
selective inhibitors for b-catenin/T-cell factor (Tcf) interactions
(Fig. 9).71 The b-catenin/Tcf protein–protein complex is a key
downstream effector of the canonical Wnt signaling pathway.
The aberrant formation of this protein–protein complex overacti-
vates Wnt target genes that cause the initiation and progression
of many cancers and ﬁbroses. The previous crystallographic and
biochemical studies revealed three hot regions for b-catenin/Tcf
PPIs, as shown in Figure 1. The contribution of each hot region
was quantitatively evaluated, and the D16/K435 and E17/K508
interactions were identiﬁed essential for the formation of the
b-catenin/Tcf complex. Bioisosteres were used to mimic the bind-
ing mode of side chain carboxylic acids of Tcf4 D16 and E17, which
led to UU-T01 with a Ki value of 3.14 ± 0.48 lM. This compound
completely disrupts b-catenin/Tcf interactions and is two orders
of magnitude more potent than dipeptide D–E. The binding mode
of the designed inhibitors was evaluated by site-directed mutagen-
esis and structure–activity relationship (SAR) studies. Further
synthesis resulted in the discovery of 11 with a Ki value of
1.35 ± 0.15 lM (unpublished result, Ji et al.) From a differentA
Figure 9. Hot spot-based design of b-catenin/T-cell factor PPI inhibitors. (A) Bioisoteric
design 12.direction, residues D16 and E17 of human Tcf4 were maintained
in the inhibitor scaffold. SiteMap72 and Multiple-Copy Simulta-
neous Search (MCSS)73 were used to map the pockets adjacent
to K435 and K508. Based on the structure of Tcf4 peptide
G13ANDE17, a peptidomimetic strategy was used to design new
inhibitors. Compound 12 was discovered with a Ki value of
1.36 ± 0.12 lM.74 The binding mode of 12 was also evaluated by
site-directed mutagenesis and SAR studies. The ethyl ester deriva-
tive of 12 can effectively penetrate the cell membrane and inhibit
canonical Wnt signaling and the growth of colorectal cancer cells.
This compound also exhibits cell-based selectivities for b-catenin/
Tcf over b-catenin/cadherin and b-catenin/adenomatous polysis
coli (APC) interactions. A further application of fragment hopping
to scaffolds 11 and 12 led to the generation of new inhibitors with
nanomolar inhibitory potency for b-catenin/Tcf interactions and
high selectivity for b-catenin/Tcf over b-catenin/cadherin and
b-catenin/APC interactions (unpublished results, Ji et al.)
Conclusion and outlook: The discovery of small-molecule PPI
inhibitors has been difﬁcult. The low success rate for discovering
PPI inhibitors was primarily ascribed to: (1) the overall character-
istic of the protein–protein interface, which is large, ﬂat, and fea-
tureless. The amount of buried surface area upon the formation
of the protein–protein complex greatly exceeds the potential bind-
ing area of a small molecule, which highlights the value of rational
design of PPI inhibitors and the need for new techniques to detect
transient pockets; (2) the compound libraries used in HTS and vir-
tual screening. The currently available compound collections were
traditionally synthesized for enzyme and receptor targets, whichB
replacement technique to design UU-T01 and 11. (B) Peptidomimetic strategy to
W. Guo et al. / Bioorg. Med. Chem. Lett. 24 (2014) 2546–2554 2553contain binding sites drastically different from those in the pro-
tein–protein surfaces. The compound survey studies indicate that
PPI inhibitors tend to be larger, more hydrophobic, more rigid,
and contain multiple aromatic rings;75 (3) the difﬁculty to attain
reliable HTS assays for some PPI targets, in particular for the weak
PPIs with large contact surfaces;76 and (4) the ﬂexibility of the pro-
tein surface around hot regions, which accounts for some failures
of virtual screening. Hot spot-based design of PPI inhibitors is a
valuable strategy for discovering PPI inhibitors. The hot spots and
hot regions of PPIs can be identiﬁed and quantitatively evaluated
by biochemical and crystallographic studies. Biologically important
and druggable concave hot regions can be identiﬁed from the pro-
tein–protein interface. Sometimes, energetic cooperativity exists
between two hot regions. The potency of a PPI inhibitor that tar-
gets a cooperative hot region can be ampliﬁed relative to the inhib-
itor that targets a hot region that is strictly additive. Fragment-size
inhibitors can be designed and synthesized to mimic the binding
mode of hot spots in a speciﬁed hot region that contributes most
to the free energy of binding. Fragment hopping can play an impor-
tant role in designing such anchor fragments with new chemo-
types. An O-ring structure can further be built into inhibitor
structures to complement the concave hot region of PPIs when
enlarging an anchor fragment.
Protein adaptability has frequently been observed for the struc-
tures around the hot regions of PPIs. Taking into account protein
adaptability in the process of generating drug-like PPI inhibitors
is critical; this is also the advantage of hot spot-based design. After
the design and validation of an anchor fragment for one concave
hot region, this anchor fragment can be evolved into a drug-like
PPI inhibitor with the consideration of protein adaptability.
Cellular proteins often use the same surface to bind with a
structurally diverse set of proteins in different organelles or cellu-
lar environments. Inside of the cell, there is a complex network of
PPIs.77 With the mapping of the drug-target network,78 the evalu-
ation and leverage of the selectivity/speciﬁcity of PPI inhibitors has
become an emerging ﬁeld. Hot spot-based design matches well
with the need to discover PPI inhibitors with high selectivity/spec-
iﬁcity because the hot spots that are essential for different binding
partners could be located in different hot regions when more than
one hot region exists on the protein surface.9 For the proteins that
use one identical hot region for interacting with multiple protein
partners the key binding elements for PPI selectivity often reside
in the protein–protein interface adjacent to the concave hot
region.74,79 Indeed, hot spot-based inhibitor design for PPI target
is still at its beginning stage, and few examples have been reported.
More techniques need to be developed, and a surge of research in
this ﬁeld can be expected in the coming years.
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